p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

Abstract

The oncogene product epidermal growth factor receptor (EGF-R), the tumour suppressor gene product p53 and anti-p53 antibodies are detectable in the serum of certain cancer patients. Increased levels of some of these products were reported in lung cancer patients after occupational asbestos exposure and after exposure to polycyclic aromatic hydrocarbons or vinylchloride. In the first step, this study investigated the possible diagnostic value of serum EGF-R, p53-protein and anti-p53 antibodies, measured by an enzyme-linked immunosorbent assay, in lung tumour patients. In addition to being investigated on a molecular epidemiological basis, these parameters were examined as biomarkers of carcinogenesis, especially with regard to asbestos incorporation effects or of radon-induced lung cancers. Also, a possible effect of cigarette smoking and age dependence were studied. A total of 116 male patients with lung or pleural tumours were examined. The histological classification was four small-cell cancers, six large-cell cancers, 32 adenocarcinomas, 47 squamous carcinomas, 12 mixed lung carcinomas, five diffuse malignant mesotheliomas and ten lung metastasis of extrapulmonary tumours. Twenty-two lung cancers and all mesotheliomas were related to asbestos, 22 lung cancers were related to ionizing radiation and 61 patients had cigarette smoke-related lung cancer. Besides these patients 50 male patients with non-malignant lung or pleural diseases were included; of the latter eight subjects suffered from asbestosis. Controls were 129 male subjects without any lung disease. No significantly elevated or decreased serum values for p53 protein, EGF-R, or anti-p53 antibodies as a function of histological tumour type, age, or degree and type of exposure (asbestos, smoking, ionizing radiation) could be found. The utility of p53-protein, EGF-R and anti-p53 antibodies as routine biomarkers for screening occupationally derived lung cancers is limited. © 1999 Cancer Research Campaign

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

“…Moreover, there was a significant correlation between increased EGFR levels, both in serum and tissues, as well as EGFR gene amplification and T-stage, which is considered a surrogate prognostic factor in MPM. Our results are comparable to those of Betta et al [21] and Schneider et al [22] who found no differences in serum values of EGFR between MPM patients with varied clinical outcomes and attributed this to the small number of cases studied. In the present study, there was a trend for patients with low serum EGFR levels to show better response to treatment compared to those with high serum EGFR >0.23 ng/dl as a cutoff value separating patients from healthy controls though the difference did not reach a statistically significant value (p = 0.09).…”

Diagnostic Value of Autoantibodies in Lung Cancer: a Systematic Review and Meta-Analysis

“…6). Comparison of pooled diagnostic parameters using all studies or all studies except for three outliers [33,36,37] showed that excluding the three studies reduced sensitivity from 0.19 to 0.17, DOR from 10 to 9 and PLR from 8.6 to 7.9, whereas it increased NLR from 0.83 to 0.85 and AUC from 0.82 to 0.91. Specificity in both cases was 0.98.…”

Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer

“…20 Serum EGFR has been the topic of relatively few reports, and the results from those studies are conflicting. In 2 studies, no significant difference was reported in serum EGFR levels between a healthy control group and patients with lung cancer 30 or patients with squamous cell carcinoma of the head and neck. 31 Some investigators identified significantly elevated levels of serum EGFR both in patients with cervical carcinoma and in patients with carcinoma in situ compared with healthy controls, 32 whereas other investigators reported significantly elevated levels of serum EGFR in patients who had lymph node-positive lung cancer compared with the levels in patients who had lymph node-negative lung cancer, but no significant difference was reported in serum EGFR levels between patients with lung cancer and a control group of patients with nonmalignant disease.…”